Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1994 May;39(3):198–204. doi: 10.1007/BF01533387

Mapping effector functions of a monoclonal antibody to GD3 by characterization of a mouse-human chimeric antibody

Paul B Chapman 1,2,✉, Stephen D Gillies 3, Alan N Houghton 1,2, Regina M Reilly 4
PMCID: PMC11038369  PMID: 7522964

Abstract

R24, a mouse monoclonal antibody against GD3 ganglioside, exhibits a wide range of in vitro effector functions. It also has the ability to bind to itself, presumably through homophilic Fab-Fab interactions, which have been proposed to contribute to its high relative avidity for GD3 and to its effector function activity. It is not known which of these characteristics is necessary for the antitumor effects observed in melanoma patients treated with R24. A mouse-human chimeric R24 (chR24) molecule has been constructed in which the GD3-binding site is preserved. Chimeric R24 demonstrates a lower level of binding to GD3 than does mouse R24 suggesting that there may be some differences between the GD3-binding sites of the two mAb or that Fc determinants can contribute to R24 avidity for GD3. The property of homophilic binding is retained by chR24, demonstrating formally that homophilic binding of R24 involves interactions between variable domains. Both R24 and chR24 fix human complement and mediate antibody-dependent cellular cytotoxicity although chR24 was slightly less efficient at the latter. Unlike R24, chR24 was not able to inhibit melanoma cell attachment to plastic surfaces and was not able to activate human T lymphocytes. We hypothesize that chR24 does not bind to GD3 with an avidity high enough to mediate these effector functions.

Key words: Monoclonal antibody, Chimeric, GD3 ganglioside, Effector function, Homophilic binding

Footnotes

Supported by Public Health Service grants PO1-CA33049 and RO1-CA57363

References

  • 1.Bajorin DF, Chapman PB, Dimaggio J, Coit DG, Kunicka JE, Wong G, Cordon-Cardo C, Urmacher C, Dantis L, Templeton MA, Oettgen HF, Houghton AN. Phase I evaluation of a combination of monoclonal antibody R24 and interleukin 2 in patients with metastatic melanoma. Cancer Res. 1990;50:7490. [PubMed] [Google Scholar]
  • 2.Chapman PB, Houghton AN. Induction of IgG antibodies against GD3 in rabbits by an anti-idiotypic monoclonal antibody. J Clin Invest. 1991;88:186. doi: 10.1172/JCI115276. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Chapman PB, Lonberg M, Houghton AN. Light-chain variants of an IgG3 anti-GD3 monoclonal antibody and the relationship between avidity, effector functions, tumor targeting, and antitumor activity. Cancer Res. 1990;50:1503. [PubMed] [Google Scholar]
  • 4.Chapman PB, Yuasa H, Houghton AN. Homophilic binding of mouse monoclonal antibodies against GD3 ganglioside. J Immunol. 1990;145:891. [PubMed] [Google Scholar]
  • 5.Cheresh DA, Pierschbacher MD, Herzig MA, Mujoo K. Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix. J Cell Biol. 1986;102:688. doi: 10.1083/jcb.102.3.688. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Cheresh DA, Pytela R, Pierschbacher MD, Klier FG, Ruoslahti E, Reisfeld RA. An Arg-Gly-Asp-directed receptor on the surface of human melanoma cells exists in a divalent cation-dependent functional complex with the disialoganglioside GD2. J Cell Biol. 1986;105:1167. doi: 10.1083/jcb.105.3.1163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Colcher D, Milenic D, Roselli M, Raubitschek A, Yarranton G, King D, Adair J, Whittle N, Bodmer M, Schlom J. Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3. Cancer Res. 1989;49:1738. [PubMed] [Google Scholar]
  • 8.Cooper LJN, Schimenti JC, Glass DD, Greenspan NS. H chain C domains influence the strength of binding of IgG for streptococcal group A carbohydrate. J Immunol. 1991;146:2659. [PubMed] [Google Scholar]
  • 9.Dippold WG, Lloyd KO, Li L, Ikeda H, Oettgen HF, Old LJ. Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies. Proc Natl Acad Sci USA. 1980;77:6114. doi: 10.1073/pnas.77.10.6114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Gillies SD, Lo K-M, Wesolowski J. High-level expression of chimeric antibodies using adapted cDNA variable region cassettes. J Immunol Methods. 1989;125:191. doi: 10.1016/0022-1759(89)90093-8. [DOI] [PubMed] [Google Scholar]
  • 11.Greenspan NS, Dacek DA, Cooper LJN. Fc region-dependence of IgG3 anti-streptococcal group A carbohydrate antibody functional affinity. I. The effect of temperature. J Immunol. 1988;12:4276. [PubMed] [Google Scholar]
  • 12.Greenspan NS, Monafo WJ, Davie JM. Interaction of IgG3 anti-streptococcal group A carbohydrate (GAC) antibody with streptococcal group A vaccine: enhancing and inhibiting effects of anti-GAC, anti-isotypic, and anti-idiotypic antibodies. J Immunol. 1987;138:285. [PubMed] [Google Scholar]
  • 13.Greenspan NS, Dacek DA, Cooper LJN. Cooperative binding of two antibodies to independent antigens by an Fc-dependent mechanism. FASEB J. 1989;3:2203. doi: 10.1096/fasebj.3.10.2666233. [DOI] [PubMed] [Google Scholar]
  • 14.Iliopoulos D, Ernst C, Steplewski Z, Jambrosic JA, Rodeck U, Herlyn M, Clark WH, Jr, Koprowski H, Herlyn D. Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to GD2/GD3 gangliosides. J Natl Cancer Inst. 1989;81:440. doi: 10.1093/jnci/81.6.440. [DOI] [PubMed] [Google Scholar]
  • 15.Liu AY, Robinson RR, Hellstrom KE, Murray ED, Jr., Chang CP, Hellstrom I. Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci USA. 1987;84:3439. doi: 10.1073/pnas.84.10.3439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Liu AY, Robinson RR, Murray ED, Jr, Ledbetter JA, Hellstrom I, Hellstrom KE. Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. J Immunol. 1987;139:3521. [PubMed] [Google Scholar]
  • 17.Marchitto KS, Kindsvogel WR, Beaumier PL, Fine SK, Gilbert T, Levin SD, Woodhouse CS, Morgan AC. Characterization of a human-mouse chimeric antibody reactive with a human melanoma associated antigen. Prog Clin Biol Res. 1989;288:101. [PubMed] [Google Scholar]
  • 18.Mueller BM, Romerdahl CA, Gillies SD, Reisfeld RA. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J Immunol. 1990;144:1382. [PubMed] [Google Scholar]
  • 19.Nakamura K, Koike M, Shitara K, Kuwana Y, Kiuragi K, Igarashi S, Hasegawa M, Hanai N. Chimeric anti-ganglioside GM2 antibody with antitumor activity. Cancer Res. 1994;54:1511. [PubMed] [Google Scholar]
  • 20.Pukel CS, Lloyd KO, Travassos LR, Dippold WG, Oettgen HF, Old LJ. GD3, a prominent ganglioside of human melanoma. Detection and characterization by mouse monoclonal antibody. J Exp Med. 1982;155:1133. doi: 10.1084/jem.155.4.1133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Shaw DR, Khazaeli MB, LoBuglio AF. Mouse/human chimeric antibodies to a tumor-associated antigen: biologic activity of the four human IgG subclasses. J Natl Cancer Inst. 1988;80:553. doi: 10.1093/jnci/80.19.1553. [DOI] [PubMed] [Google Scholar]
  • 22.Vadhan-Raj S, Cordon-Cardo C, Carswell EA, Mintzer D, Dantis L, Duteau C, Templeton MA, Oettgen HF, Old LJ, Houghton AN. Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. J Clin Oncol. 1988;6:1636. doi: 10.1200/JCO.1988.6.10.1636. [DOI] [PubMed] [Google Scholar]
  • 23.Welt S, Carswell EA, Vogel C-W, Oettgen HF, Old LJ. Immune and nonimmune effector functions of IgG3 mouse monoclonal antibody R24 detecting the disialoganglioside GD3 on the surface of melanoma cells. Clin Immunol Immunopathol. 1987;45:214. doi: 10.1016/0090-1229(87)90036-5. [DOI] [PubMed] [Google Scholar]
  • 24.Welte K, Miller G, Chapman PB, Yuasa H, Natoli E, Kunicka JF, Cordon-Cardo C, Buhrer C, Old LJ, Houghton AN. Stimulation of T cell lymphocyte proliferation by monoclonal antibodies against GD3 ganglioside. J Immunol. 1987;139:1763. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES